相关实验视频

Updated: Jul 8, 2025

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

在患有子宫内膜异位症的女性中,试管婴儿刺激方案和结果

Eduardo Goyri¹, Graciela Kohls¹, Juan Garcia-Velasco¹

¹IVI Madrid, Madrid, Spain.

Best practice & research. Clinical obstetrics & gynaecology

|December 15, 2023

概括

对于患有子宫内膜异位症的女性来说,GnRH抗体协议和孕激素主导卵巢刺激 (PPOS) 提供了安全有效的辅助生殖选择,改善了生育结果. 无论选择哪种方案,都建议对IVF进行早期干预.

科学领域:

生殖医学生殖医学
妇科妇科妇科妇科
在体外受精过程中受精.

背景情况:

子宫内膜异位症显著影响生育年龄妇女的生育能力.
辅助生殖治疗 (ART) 对于管理与子宫内膜异位症相关的不孕症至关重要.
优化卵巢刺激方案是改善这些患者体外受精成功率的关键.

研究的目的:

审查和比较不同卵巢刺激协议的疗效和安全性,用于体外受精 (IVF) 在女性子宫内膜异位症.
评估性腺激素释放激素 (GnRH) 对抗剂协议和孕激素主导卵巢刺激 (PPOS) 在子宫内膜异位症患者中的作用.
强调早期干预和孕产妇内膜异位症妇女的生育能力保护的重要性.

主要方法:

对 GnRH 激动剂长期方案与短期 GnRH 激动剂对抗方案的比较分析.
作为一种较新的策略,对前列腺激发性卵巢刺激 (PPOS) 的评估.
审查与玻璃化技术和冷保存相关的结果.

主要成果:

基因激素抗剂方案的疗效与传统的基因激素抗剂方案的疗效相当,安全性更好.
孕激素辅助卵巢刺激 (PPOS) 正因良好的结果和患者接受而获得患者的认可.
没有单一的刺激方案被证明是绝对优越的;早期的ART干预是有益的.

结论:

在接受试管婴儿的子宫内膜异位症妇女中,GnRH对抗剂协议和PPOS是卵巢刺激的有效和安全选择.
在外科切除之前,建议对患有子宫内膜瘤的女性进行生育保护咨询.
重复的卵细胞或胚胎冷保存周期可以提高生育潜力.

关键词:

子宫内膜异位症是什么?子宫内膜异位症是什么?保存生育能力保护生育能力卵巢刺激方案卵巢刺激方案卵巢外科手术卵巢外科手术

更多相关视频

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Published on: January 22, 2022

相关概念视频

In Vitro Fertilization

In Vitro Fertilization

In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...

Meiosis II

Meiosis II

Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each...

Infertility in Females

Infertility in Females

Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...

Oogenesis

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...